Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.blre.2020.100707 http://scihub22266oqcxt.onion/10.1016/j.blre.2020.100707 32425294!7227559!32425294     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood+Rev 2021 ; 45 (ä): 100707 Nephropedia Template TP {{tp|p=32425294|t=2021. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes |pdf=|usr=}}{{32425294}} gab.com Text Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes JO: Blood Rev http://www.kidney.de/pget.php?&tw=1&pmid=32425294 #FOAvip A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a "Cytokine Storm Syndrome" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS. Twit Text FOAVip Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes ????Blood Rev http://www.kidney.de/pget.php?&tw=1&pmid=32425294 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32425294 #FOAvip English Wikipedia <ref>{{Cite pmid|32425294}}</ref> Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes #MMPMID32425294 England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC Blood Rev 2021[Jan]; 45 (ä): 100707 PMID32425294show ga A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a "Cytokine Storm Syndrome" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS. |Adrenal Cortex Hormones/therapeutic use[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Biomarkers/blood[MESH] |C-Reactive Protein/immunology/metabolism[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*immunology/pathology/virology[MESH] |Castleman Disease/drug therapy/*immunology/pathology[MESH] |Clinical Trials as Topic[MESH] |Cytokine Release Syndrome/drug therapy/*immunology/pathology/virology[MESH] |Ferritins/blood/immunology[MESH] |Gene Expression Regulation[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Immunotherapy, Adoptive/adverse effects[MESH] |Interleukin-1/antagonists & inhibitors/blood/immunology[MESH] |Interleukin-6/antagonists & inhibitors/blood/immunology[MESH] |Lymphohistiocytosis, Hemophagocytic/drug therapy/*immunology/pathology[MESH] |SARS-CoV-2/*pathogenicity[MESH]Weathering the COVID-19 storm: Lessons from hematologic cytokine syndr(epmc).pdf DeepDyve Pubget Overpricing